Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 04, 2020 / 08:00PM GMT
Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

Hi, everyone. This is Eun Yang, a biotech analyst with Jefferies. Welcome to Jefferies Virtual Healthcare Conference. It is my pleasure to host a fireside chat with the BioMarin management: J.J. Bienaimé, Chairman and CEO; Hank Fuchs, President of Worldwide R&D; and Brian Mueller, acting CFO.

Before we start the Q&A, J.J. will give us a brief opening remarks. J.J.?

Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO

©,-&

Thank you, Eun. So we appreciate the opportunity to participate in your virtual healthcare conference today. As you know, this past Sunday, we shared highlights from 4 years of clinical data with ROCTAVIANÂ gene therapy for the treatment of severe hemophilia A. We are very pleased that at 4 years after treatment, patients on our study remained off prophylactic therapy and have experienced less than 1 bleed per year on a cumulative basis over the 4 years of the study.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot